ReviewMetabolic brain disease2026
Targeting microbiota-gut-brain axis with phytochemicals: a mechanistic roadmap for dementia.
Review in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dementia is a growing global health concern, with limited therapeutic options. Treating dementia is a crucial but often overlooked part of neurological care for the elderly. The gut microbiota plays an essential role in the bidirectional interaction between the gut and the brain. Growing evidence suggests that gut microbes, which can influence neural development, modulate neurotransmission, and affect behaviour, may contribute to the development and pathophysiology of various neurodevelopmental, neuropsychiatric, and neurological disorders like dementia. This underscores the need for new interventions targeting the gut-brain axis(GBA). This review highlights the role and application of phytochemicals in treating dementia by modifying the GBA. We outline the harmful relationship between dementia and microbial dysbiosis, focusing on abnormal tryptophan- kynurenine metabolism, impaired SCFA synthesis, disruption of the BBB, and altered microglial activation states. Nevertheless, the potential of different phytochemicals, such as flavonoids, alkaloids, terpenoids, and polyphenols, to enhance neuroprotective metabolite production, restore microbial balance, regulate inflammatory signalling (e.g., NF- κb, Nrf 2, MAPK, and TLR 4), and improve synaptic plasticity via pathways like BDNF-CREB, is under investigation. Key bioactive compounds like berberine, resveratrol, and curcumin are being tested for their efficacy concerning molecular targets and outcomes in both preclinical and clinical models of cognitive decline. In addition to specific phytochemicals, probiotic and prebiotic synergistic approaches may enhance gut homeostasis and cognitive resilience, opening avenues for functional food- based treatments. Although promising, challenges to clinical application remain, such as low bioavailability, standardisation issues, and interindividual microbiome variability. This review emphasises prospects for precision nutrition and microbiome- targeted therapies in dementia, discusses translational barriers, and summarises recent data on phytochemical modulation of the GBA in dementia.
Indexed as
Identifiers
42340489What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.